Education
About Us
Working with TipRanks
Follow Us
Kaleido Biosciences Inc (KLDO)
OTHER OTC:KLDO
Total Valuation
Kaleido Biosciences has a market cap or net worth of $4.26K. The enterprise value is ―.
Market Cap$4.26K
Enterprise Value―
Share Statistics
Kaleido Biosciences has 42,622,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding42,622,560
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
Kaleido Biosciences’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)0.00
Return on Assets (ROA)0.00
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee0.00
Profits Per Employee0.00
Employee Count76
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kaleido Biosciences is 0.00. Kaleido Biosciences’s PEG ratio is 0.00.
PE Ratio0.00
PS Ratio0.00
PB Ratio0.00
Price to Fair Value0.00
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.00
Income Statement
In the last 12 months, Kaleido Biosciences had revenue of 0.00 and earned 0.00 in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income0.00
Net Income0.00
EBITDA0.00
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Kaleido Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-411.15
52-Week Price Change-25.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)345.00
Important Dates
Kaleido Biosciences upcoming earnings date is Nov 7, 2022, TBA Not Confirmed.
Last Earnings DateAug 10, 2022
Next Earnings DateNov 7, 2022
Ex-Dividend Date―
Financial Position
Kaleido Biosciences as a current ratio of 0.00, with Debt / Equity ratio of 0.00%
Current Ratio0.00
Quick Ratio0.00
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Kaleido Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kaleido Biosciences EV to EBITDA ratio is 0.00, with an EV/FCF ratio of 0.00.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
Kaleido Biosciences has $0.00 in cash and marketable securities with $14.91M in debt, giving a net cash position of $0.00 billion.
Cash & Marketable Securities$0.00
Total Debt$14.91M
Net Cash$0.00
Net Cash Per Share$0.00
Tangible Book Value Per Share$0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kaleido Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―